



2026 Europe Interchange

THE FUTURE IS CONNECTED: STANDARDS AND AI POWERING DIGITAL TRANSFORMATION



MILAN, ITALY | MAIN CONFERENCE: 20-21 MAY | TRAININGS & WORKSHOPS: 18, 19, & 22 MAY

Evinova's USDM-Driven Approach to Protocol Standardization and Study Design Optimization

Aleksandra Wawrzycka, Associate Director Data Standards, Evinova

Jeffrey Eker, Study Designer Head of Product, Evinova

Speakers



Aleksandra „Ola” Wawrzycka
Associate Director Data Product Operations
Evinova



Jeffrey Eker
Study Designer Head of Product
Evinova




Our Evinova Study Designer mission is to...

Create a trusted agentic studio that accelerates trial design, authoring, and downstream system configuration to one week.

*Our AI-native platform is the accelerant. **USDM** is the interoperability backbone that enables the transformation.*



Enabling ClinDev and ClinOps experts to accelerate drug development collaboratively requires standards




It all started with protocol digitization...

- Clinical expertise was trapped in unstructured PDFs- inaccessible for systematic analysis or reuse
- Manual data extraction was prone to inconsistencies and infeasible for large volume of CSPs
- Without standardization, there was no cross-study analysis or institutional knowledge preservation
- **Decades of trial expertise was lost with no structured way to capture and transfer**




USDM was the natural choice.

- Vendor-neutral format prevents lock-in to proprietary systems
- Comprehensive coverage of all clinical trial elements
- Reusable library of standardized terms
- Enabler of downstream applications like cost estimation, EDC auto build, etc.





A team of AI agents parses PDF protocols into USDM



Goal: Transform unstructured protocol PDFs into USDM JSON with human-in-the-loop quality control

Safeguards:
Constrained schemas, validation rules, provenance tags, and audit logs

Integration:
Open-source components for parsing and validation; export as USDM JSON for downstream tools

Our published findings in Nature.com

In our **Nature.com** publication, we provided evidence that the implementation of digital health technology in clinical trials improves patient experience with accelerated timelines and reduced costs:

60%

improvement
in patient
experience

40%

of on-site visits
could be
eliminated⁽¹⁾

15-30%

acceleration
in timelines⁽²⁾

43%

reduction in
cost⁽³⁾

Improved health outcomes

We have also shown that digital health technology can reduce carbon emissions by **20-45%**



<https://www.nature.com/articles/s41591-023-02489-z>

1. Assessment of 91 protocols across 50% of indications of total market, when utilising clinical validated devices.
2. Acceleration of 6 months in CRESCENDO Study
3. Cost reduction in DAPA-MI Study



naturemedicine

Explore content ▾ About the journal ▾ Publish with us ▾

[nature](#) > [nature medicine](#) > [comment](#) > article

Comment | Published: 16 August 2023

Implementation of digital health technology in clinical trials: the 6R framework

[Cristina Ortega Durán](#) , [Matthew Bonam](#), [Elisabeth Björk](#), [Rod Hughes](#), [Serban Ghiorguiu](#), [Cristian Massacesi](#), [Alicyn Campbell](#), [Emmette Hutchison](#), [Menelas N. Pangalos](#) & [Susan Galbraith](#)

Nature Medicine 29, 2693–2697 (2023) | [Cite this article](#)

4613 Accesses | 114 Altmetric | [Metrics](#)

AstraZeneca has introduced digital health solutions into clinical trials, demonstrating improved patient experience, accelerated timelines and reduced costs.

Clinical trials usually follow a site-based model that is centered around in-person patient visits for recruitment, interventions, assessments and follow-up¹. Although patients benefit from in-person contact, reliance on clinical visits can represent a large burden for many patients, who must navigate challenges due to the time, logistics and cost of attendance². The use of digital technology has been proposed to address some of the potential inefficiencies associated with the site-based clinical trial model, with the broad aim of optimizing the experience of participants in clinical trials³.

The Result: USDM driven efficiency

enabling faster study design build times



Study Designer

Design
Costing
Benchmarks
Feasibility
Document
Authoring AI

Design studies with the power of data and AI, to accelerate **productivity and study outcomes.**

- Fewer design iterations through explicit, shared semantics
- Reduced handoffs and rework via a single source of truth
- Earlier feasibility and burden checks to streamline decisions
- Instant querying of existing protocols to inform decisions and enable downstream automation


Delivered benefits for large pharma

>\$100M in first year and **\$354M** by year 4

30% improvement patient experience

14% improvement carbon emissions


26% improvement patients per site



Exploring Extensions of USDM

Our biggest challenge is extending the data model to contemplate broader study context, such as cost and other operational data.

Based on our learnings collaborating with CDISC, we are in the process of implementing a CostItem Class which would allow USDM to capture various study costs such as Labs and Procedures in a standard way.





**We look forward to engaging
with you at the...**

- 360i Technology Vendor Roundtable
- Innovator Council
- DDF Solution Collaboration Forum

Questions?





Thank You!

